Results for
"[search-keyword]"
Sponsor content
165 result(s) found, displaying 91 to 100
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Prescription medicine registrationActive ingredients: insulin degludec; liraglutide.
-
Australian Public Assessment Report (AusPAR)Ozempic (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
-
Australian Public Assessment Report (AusPAR)New AusPAR for Fiasp, Fiasp Penfill, Fiasp FlexTouch (insulin aspart rys) for the treatment of diabetes mellitus
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Insulin degludec (rys) and Insulin aspart (rys)
-
Prescription medicine registrationActive ingredients: insulin aspart (rys).
-
Prescription medicine registrationActive ingredients: insulin degludec (rys), insulin aspart (rys).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRESIBA PENFILL insulin degludec (rys) 100 U/mL solution for injection multidose cartridge.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TRESIBA FLEXTOUCH insulin degludec (rys) 200 U/mL solution for injection multidose cartridge.